Skip to content
Govbase
Govbase
Congress·In Committee·H.R. 2450

Prescription Drug Transparency and Affordability Act

Bipartisan House Bill Targets Pharmacy Middlemen to Reveal Secret Drug Rebates and Costs

This bill is currently in the early stages of the legislative process and is being reviewed by three different House committees. It is actively moving forward as it waits for these committees to finish their work. There are no upcoming votes scheduled at this time.

Legislative Progress

House
Senate
President
Law
Could go either way

There is strong bipartisan interest in lowering drug costs by regulating middlemen. However, similar bills often face heavy lobbying from the insurance industry which can slow them down.

Key Points

HealthcareEconomy Finance

Impact Analysis

Personal Impact

Life & Work

Small business owners who sponsor group health plans will receive summary reports from PBMs showing estimated net prices, cost per claim, fee structures, and cost per participant. This gives smaller employers better information to shop for PBM services and negotiate better deals. Employers with 100+ employees get even more detailed drug-level data. The transparency could help businesses that currently lack bargaining power against large PBMs.

3
2
3
4
+2
ImpactCertaintyScopeDurationSentiment

Programs

Disabilities

Milestones

2 milestones2 actions
Mar 27, 2025House

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.

Mar 27, 2025

Introduced in House

The bill was officially filed and given a number. It now enters the legislative queue.

Votes

No votes have been recorded for this legislation yet.

Source Information

Document Type

Congressional Bill

Official Title

Prescription Drug Transparency and Affordability Act

Bill NumberHR 2450
Congress119th Congress
ChamberHouse of Representatives
Latest ActionReferred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Sponsor

Cosponsors

(3)
D: 1R: 2

Analysis generated by AI. Always verify with official sources.